Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Universiteit Antwerpen
Modality
UNKNOWN
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06296082CT.gov Comparative Study of the Effects of Dry Needling and Botulinum Toxin Type A as a Treatment for Lower Limb Post-stroke Spasticity | — | Recruiting | — | — | — |
NCT04908423CT.gov Xeomin® and Gait Related Mobility After Stroke | — | Recruiting | — | — | — |
NCT04544280CT.gov Effect of Repeated Injections of Higher Doses of Botulinum Toxin on Lower Limb of Spastic Hemiplegic Patients on Gait. | — | Completed | — | — | — |
NCT02749591CT.gov Comparative Hybrid Effects of Combining BoNT-A With Robot-assisted or Mirror Therapy for U/E Spasticity Stroke Patients | — | Completed | — | — | — |
NCT02469948CT.gov Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities | — | Unknown | — | — | — |
NCT02321436CT.gov Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression | — | Completed | — | — | — |
NCT01945684CT.gov A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity | — | Completed | — | — | — |
NCT01603615CT.gov BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity | — | Completed | — | — | — |
NCT02557737CT.gov Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities | — | Unknown | — | — | — |
NCT01603602CT.gov BOTOX® Treatment in Pediatric Upper Limb Spasticity | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT02586142CT.gov Botulinum Toxin Injections by Ultrasounds Guidance and Stretching Exercise in Spastic Toe Clawing | — | Completed | — | — | — |
NCT00216411CT.gov Effects on Quality of Life Following Dysport Treatment in Post-stroke Spasticity of the Arm | — | Completed | — | — | — |
NCT00651690CT.gov Study of Responsiveness of Seven Functional Tasks in Patients With Poststroke Upper Limb Spasticity With Botulinum Toxin Type A Treatment | — | Completed | — | — | — |
NCT00076687CT.gov Safety Study of Botulinum Toxin Type A in Post-Upper Limb Stroke Patients With Reduced Lung Function | — | Completed | — | — | — |
NCT00651729CT.gov Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity | — | Completed | — | — | — |
NCT00234546CT.gov Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Xeomin® (this asset) | Universiteit Antwerpen | Approved | BB · 70 |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Clopidogrel | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Xeomin®
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Pain Syndrome | — | P3 | B · 60 |
| Migraine Disorder | — | P3 | B · 60 |
| Primary Dysmenorrhea | — | P3 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Xeomin® in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/xeomin-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →